Back to Bills
SENATE-BILL 2292119th Congress

SENATE-BILL 2292: S.2292 - Over-the-Counter Monograph Drug User Fee Amendments

Introduced: July 15, 2025
Status: Reported by Committee
R.for.R

AI-Powered Summary

Generated by AI Analysis

SENATE-BILL 2292 aims to amend the Federal Food, Drug, and Cosmetic Act to enhance the regulation and availability of over-the-counter (OTC) monograph drugs by streamlining the user fee program. The legislation addresses major themes of public health, consumer access to safe medications, and regulatory transparency. Key provisions include the establishment of user fees for OTC drugs, which may influence their cost and availability, and a requirement for the FDA to report on regulatory progress, thereby promoting accountability. The bill emphasizes the use of voluntary consensus standards for testing procedures, potentially improving drug quality. Implementation will involve the FDA adapting its regulatory processes to incorporate these fees and reporting requirements, although specific timelines are not detailed. Potential impacts include improved access to safe medications for consumers, though concerns about transparency and public participation in the regulatory process may arise, highlighting the balance between revenue generation and public health priorities.

Demographic Impact Analysis

AI Demographics Analysis

Summary

Overall Constitutional Implications

The bill's provisions regarding user fees for OTC drugs could create barriers to access for various demographic groups, particularly those with lower incomes or specific health needs. This raises constitutional concerns about equal protection and the right to health.

Key Individual Rights Affected

  • Right to Health and Safety
  • Equal Protection under the Law
  • Due Process in Regulatory Processes

Constitutional Provisions

  • Fourteenth Amendment - Equal Protection Clause
  • Fifth Amendment - Due Process Clause

Potential Constitutional Challenges

The bill may face challenges based on its disproportionate impact on low-income individuals and marginalized groups, arguing that it violates equal protection principles. Additionally, the lack of transparency in the regulatory process could lead to due process concerns.

Summary

SENATE-BILL 2292 aims to streamline the regulatory framework for OTC drugs but raises significant constitutional implications regarding individual rights. The potential for increased costs and reduced access to essential medications could disproportionately affect vulnerable populations, leading to violations of equal protection and due process rights. The bill's impact on public health must be balanced against these constitutional concerns to ensure equitable treatment for all individuals.

Constitutional Analysis

R.for.R

This bill has been analyzed for constitutional compliance using AI-powered analysis of constitutional principles and precedents.

Analysis generated using AI-powered review of constitutional principles and legal precedents.

Take Action

Text 50409

💡 How to use:

These links will start a conversation with ResistBot. When prompted, mention S. 2292 to reference this bill.

Contact Your Representatives

Write to YOUR elected officials about this bill

Rate This Bill

Sign in to save a private rating for this bill and track your civic engagement over time.

Sign In Free

Policy Topics

Timeline

July 15, 2025

Bill Introduced

Current

Reported by Committee

June 12, 2026

Last Updated

Ask the Constitutional AI About This Bill

Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.

Sign In Free to Chat